Relative Bioavailability Study on a Single Dose of GW842166X in Healthy Male and Female Subjects.

A 2 Part Open-label, Randomised, Crossover Study to Compare the Effects of Formulation, Food and Particle Size on the Pharmacokinetic Profiles of a Single 175mg Dose of GW842166X in Healthy Male and Female Volunteers

GW842166X is a selective non-cannabinoid CB2 receptor agonist, which is undergoing clinical development as a novel oral treatment for inflammatory pain. The purpose of the study is to compare the effects of formulation, food and particle size on the pharmacokinetic profiles of a single 175mg dose of GW842166X in healthy male and female volunteers.

Inclusion Criteria:

• Body weight >50 Kg and BMI within the range 18.5-29.9 Kg/m2 inclusive.
• Healthy as judged by a responsible physician.

Exclusion Criteria:

• Positive pre-study urine screen for drugs of abuse or alcohol breath test.